Search Result

Results for "

?epidermal growth factor receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (37) IGF-1R (1) VEGFR (1) Antibody-Drug Conjugates (ADCs) (4) Apoptosis (2) BMX Kinase (1) Btk (1) Calcium Channel (2) CDK (1) Drug-Linker Conjugates for ADC (1) ERK (2) MEK (1) Phosphatase (2) Reactive Oxygen Species (2) STING (1) Topoisomerase (3)
By Research Areas:	Cancer (37) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	Alkynes (5)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Targets Recommended: EGFR FGFR VEGFR TGF-beta/Smad PDGFR TGF-β Receptor GHSR IGF-1R Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-U00002

ZD-4190	VEGFR EGFR	Cancer
ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.

HY-12806

AG1557

EGFR Cancer

AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC₅₀ value of 8.194 .

AG1557	EGFR	Cancer
AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC₅₀ value of 8.194 .

HY-P1085

Epidermal Growth Factor Receptor Peptide (985-996)	EGFR	Cancer
Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .

HY-160613

EGFR/HER2-IN-11	EGFR	Cancer
EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC₅₀s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI₅₀ of 601 nM .

HY-132259

Depatuxizumab mafodotin ABT-414	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research .

HY-115716

EGFR-IN-17

EGFR Cancer

EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC₅₀ 0.0002 μM) to overcome C797S-mediated resistance.

EGFR-IN-17	EGFR	Cancer
EGFR-IN-17 is a potent and selective inhibitor of the **epidermal growth factor receptor ( IC₅₀** 0.0002 μM) to overcome C797S-mediated resistance.

HY-P9905

Cetuximab Maximum Cited Publications 25 Publications Verification C225	EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-114456

Ganglioside GM3	Others	Metabolic Disease
Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .

HY-162099

VEGFR-IN-4	EGFR	Cancer
VEGFR-IN-4 (Compound 6e) is an epidermal growth factor receptor (EGFR) inhibitor. VEGFR-IN-4 has potent antiproliferative activity with an IC₅₀ value of 24.6nM against HCC827 cells .

HY-18963

Lavendustin A RG-14355
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-100214

EAI001
EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC₅₀ value of 24 nM for EGFR ^L858R/T790M. EAI001 can be used for research of cancer .

HY-N8473

Pericosine A (+)-Pericosine A	Topoisomerase	Cancer
Pericosine A ((+)-Pericosine A) is a topoisomerase II (Topoisomerase II) inhibitor that can be isolated from the Periconia byssoides strain. Pericosine A has significant antitumor activity in vitro and in vivo and can be used in cancer research. Pericosine A also inhibits the protein kinase epidermal growth factor receptor .

HY-19909

NRC-2694	EGFR	Cancer
NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P1799

[pTyr5] EGFR (988-993)	Phosphatase	Others
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P9985

Disitamab vedotin 1 Publications Verification RC48	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .

HY-P1799A

[pTyr5] EGFR (988-993) (TFA)	Phosphatase	Others
[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-144048

EGFR-IN-31	EGFR	Cancer
EGFR-IN-31 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2) .

HY-144049

EGFR-IN-32	EGFR	Cancer
EGFR-IN-32 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-32 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185297A1, compound 2) .

HY-139300

Epitinib HMPL-813	EGFR	Cancer
Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer . Epitinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-149517

EGFR/BRAFV600E-IN-2	EGFR	Cancer
E07 aptamer is an aptamer that targets human epidermal growth factor receptor (hEGFR). E07 aptamer can compete with EGF for binding, binds to a novel epitope on EGFR. E07 aptamer binds to cells expressing EGFR, blocks receptor autophosphorylation, and prevents proliferation of tumor cells in three-dimensional matrices. E07 aptamer can be used for tomor disease research .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-139300A

Epitinib succinate HMPL-813 succinate	EGFR	Cancer
Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer . Epitinib (succinate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145867

EGFR-IN-45	Topoisomerase EGFR CDK Apoptosis	Cancer
EGFR-IN-45 is a potent epidermal growth factor receptor (EGFR) pan inhibitor, with IC₅₀s of 0.4 µM and 1.6 µM for EGFR and CDK2, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces apoptosis .

HY-150781

EGFR-IN-71	EGFR	Cancer
EGFR-IN-71 is a potent narrow spectrum epidermal growth factor receptor (EGFR) inhibitor with IC₅₀ values of 3.7 μM. EGFR-IN-71 can be used for researching chordoma . EGFR-IN-71 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-144056

EGFR-IN-39	EGFR	Cancer
EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .

HY-144055

EGFR-IN-38	EGFR	Cancer
EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4) .

HY-144054

EGFR-IN-37	EGFR	Cancer
EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7) .

HY-144052

EGFR-IN-35	EGFR	Cancer
EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11) .

HY-144051

EGFR-IN-34	EGFR	Cancer
EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12) .

HY-144050

EGFR-IN-33	EGFR	Cancer
EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) .

HY-100499

Tyrphostin AG 528 Tyrphostin B66; AG 528	EGFR	Cancer
Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC₅₀s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC₅₀s of 4.9 μM for epidermal growth factor receptors (EGFR) and 2.1 μM for ErbB2 . Tyrphostin AG 528 is also an anticancer agent .

HY-100338

CNX-500
CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC₅₀ of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn .

HY-19985A

(3S,4S)-PF-06459988	EGFR	Cancer
(3S, 4S)-PF-06459988 is the S enantiomer of PF-06459988 with less active. PF-06459988 is a potent irreversible inhibitor of T790M mutant epidermal growth factor receptor (EGFR). PF-06459988 has excellent selectivity against EGFR wild-type while possessing a minimally reactive electrophile that reduces the propensity of off-target labeling .

HY-150782

UNC-CA359	EGFR	Cancer
UNC-CA359 is a potent **epidermal growth factor receptor (EGFR) inhibitor, with an IC₅₀** value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-125102

AZ12253801	IGF-1R	Cancer
AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC₅₀ of 17 nmol/L. The IC₅₀ for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.

HY-138298A

Trastuzumab deruxtecan 1 Publications Verification DS-8201; DS-8201a	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-*human epidermal* growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**. Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-101959

Tyrphostin AG213 AG213	EGFR Topoisomerase	Cancer
Tyrphostin AG213 (AG213) is an inhibitor of epidermal growth factor receptor (EGFR) protein tyrosine kinase (IC₅₀=0.85 μM). Tyrphostin AG213 inhibits tyrosine kinase activity IC₅₀=2.4 μM) and topoisomerase II (IC₁₀₀=50 μM). Tyrphostin AG213 can induce nonapoptotic cell programmed death in tumor cells .

HY-138298

Trastuzumab deruxtecan (solution) 1 Publications Verification DS-8201 (solution); DS-8201a (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-*human epidermal* growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**. Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-144680

BLU-945 ZL-2313	EGFR	Cancer
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC) .

HY-152098

HX103	EGFR	Cancer
HX103 is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe. HX103 inhibits EGFR 19 del, EGFR L858R, EGFR wild type and EGFR T790M with IC₅₀s of 1.3, 1.5, 4.0 and 977 nM, respectively. HX103 can be used for quantifying active-EGFR to predict agent sensitivity in NSCLC patients with EGFR-activating mutations .

HY-148460

Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine	Drug-Linker Conjugates for ADC EGFR STING	Cancer
Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine is an immune stimulator antibody conjugate (ISAC) comprising an *anti-human epidermal* growth factor receptor 2 (HER2) antibody, a STING** agonist (ADU-S100) and a linker. Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine can be uesd for cancer research (WO2018200812A1; example 5) .

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .

HY-101522

CHMFL-EGFR-202	EGFR BMX Kinase Btk MEK	Cancer
CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC₅₀s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ～10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines .

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library

1835 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1835 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

HY-L074

Anti-Breast Cancer Compound Library

1953 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 1953 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Target	Research Area

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .

HY-P1085

Epidermal Growth Factor Receptor Peptide (985-996)	EGFR	Cancer
Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .

HY-P1799

[pTyr5] EGFR (988-993)	Phosphatase	Others
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P1799A

[pTyr5] EGFR (988-993) (TFA)	Phosphatase	Others
[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .

Species:	Human (10) Rhesus Macaque (3) Mouse (2) Rat (1) Cynomolgus (2) Canine (1)
Tag:	His (14) Myc (1) GST (2) Fc (4)
Source:	HEK293 (13) Sf9 insect cells (5) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70189

	EGFR vIII Protein, Human (HEK293, His) rHuEpidermal growth factor receptor/EGFR vIII, His; Epidermal growth factor receptor; EGFR; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR	Human	HEK293
	The EGFRvIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, His) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR vIII Protein, Human (HEK293, His) is 354 a.a., with molecular weight of 61-75 kDa.

HY-P72988

	EGFR Protein, Mouse (HEK293, Fc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Mouse (HEK293, Fc) is 623 a.a., with molecular weight of ~142.57 kDa.

HY-P72989

	EGFR Protein, Mouse (HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, His) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Mouse (HEK293, His) is 647 a.a., with molecular weight of ~100 kDa.

HY-P72990

	EGFR Protein, Rat (HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rat	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Rat (HEK293, His) is the recombinant rat-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Rat (HEK293, His) is 622 a.a., with molecular weight of 93-110 kDa.

HY-P72986

	EGFR Protein, Canine (sf9, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Canine	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein participate in the NF-kappa-B signaling pathway. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein, Canine (sf9, His) is the recombinant canine-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Canine (sf9, His) is 618 a.a., with molecular weight of ~87.2 kDa.

HY-P72987

	EGFR Protein, Human (sf9, His-GST) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (sf9, His-GST) is the recombinant human-derived EGFR protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of EGFR Protein, Human (sf9, His-GST) is 543 a.a., with molecular weight of ~89.1 kDa.

HY-P70608

	EGFR Protein, Human (HEK293, Fc) Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (HEK293, Fc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Human (HEK293, Fc) is 354 a.a., with molecular weight of 90-120 kDa.

HY-P700485

	EPS15 Protein, Human (His) Eps15 epidermal; growth factor receptor pathway substrate 15; 2410112D09Rik; epidermal growth factor receptor substrate 15; epidermal growth factor pathway substrate 15; protein AF-1p	Human	E. coli
	EPS15 is a multifunctional protein that regulates cell growth, controls mitotic signaling, and contributes to receptor tyrosine kinase (RTK) internalization, particularly affecting EGFR. As a clathrin adapter, EPS15 is critical for the assembly and maturation of clathrin-coated pits (CCP), affecting the endocytosis of molecules such as ITGB1 and transferrin receptor (TFR). EPS15 Protein, Human (His) is the recombinant human-derived EPS15 protein, expressed by E. coli , with N-6*His labeled tag. The total length of EPS15 Protein, Human (His) is 142 a.a., with molecular weight of 20.9 kDa.

HY-P74177

	EGFR Protein, Human (621a.a, HEK293, Fc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR Protein, Human (621a.a, HEK293, Fc) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-hFc labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, Fc) is 621 a.a., with molecular weight of 110-160 kDa.

HY-P70613

	EGFR Protein, Human (621a.a, HEK293, His) Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, His) is 621 a.a., with molecular weight of 90-120 kDa.

HY-P73517

	EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is 621 a.a., with molecular weight of ~99.5 kDa.

HY-P75259

	EGFR Protein, Cynomolgus (sf9, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (sf9, His) is the recombinant cynomolgus-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (sf9, His) is 621 a.a., with molecular weight of ~70.1 kDa.

HY-P75260

	EGFR Protein, Cynomolgus (HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (HEK293, His) is 621 a.a., with molecular weight of ~93.8 kDa.

HY-P702751

EGFR Protein, Human (sf9, GST)

Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1
Human Sf9 insect cells

HY-P75256

	EGFR Protein, Rhesus Macaque (sf9, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (sf9, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Rhesus Macaque (sf9, His) is 645 a.a., with molecular weight of ~70.1 kDa.

HY-P75258

	EGFR Protein, Rhesus Macaque (HEK293, Fc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Rhesus Macaque (HEK293, Fc) is 645 a.a., with molecular weight of ~95.4 kDa.

HY-P75257

	EGFR Protein, Rhesus Macaque (645a.a, HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (645a.a, HEK293, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-10*His labeled tag. The total length of EGFR Protein, Rhesus Macaque (645a.a, HEK293, His) is 621 a.a., with molecular weight of ~93.85 kDa.

HY-P700409

	EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-Myc, N-10*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is 621 a.a., with molecular weight of 73.6 kDa.

HY-P700693

CLEC14A Protein, Human (HEK293, His)

Epidermal growth factor receptor 5; EGFR-5; EGFR 5; EGFR5; C14orf27; UNQ236; PRO269; CEG1
Human HEK293

Cat. No.	Product Name		Classification